This study is testing a combination of three drugs: avutometinib, defactinib, and letrozole, to see if they help treat low-grade serous ovarian cancer (LGSOC). LGSOC is a type of cancer that affects the ovaries, and the researchers want to find out if this drug mix works and is safe. To join the study, you must be a woman aged 18 or older with confirmed LGSOC, and meet other health criteria, such as having a good heart and organ function. You can't join if you've had major surgery recently, certain medical conditions, or can't take oral medications. The study won't accept you if you're pregnant, breastfeeding, or have allergies to the study drugs.
- Study Length: Participants must be committed to the study duration which may involve multiple visits.
- Compensation: Compensation might be available for participation.
- Risks: There could be side effects, so it's important to discuss with your doctor.
Consider talking to your doctor to see if this study is a good fit for you.
How understandable was the trial content above?
Hard to understand
Easy to understand